Wellness products company Nature’s Sunshine (NASDAQ:NATR) will be reporting results this Wednesday afternoon. Here’s what to expect.
Nature's Sunshine missed analysts’ revenue expectations last quarter, reporting revenues of $117 million, up 1.9% year on year. It was a disappointing quarter for the company, with a significant miss of analysts’ EBITDA estimates and a significant miss of analysts’ EPS estimates.
Is Nature's Sunshine a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Nature's Sunshine’s revenue to be flat year on year, slowing from the 12% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Nature's Sunshine rarely misses Wall Street’s revenue estimates.
Looking at Nature's Sunshine’s peers in the personal care segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Estée Lauder delivered year-on-year revenue growth of 6.8%, beating analysts’ expectations by 1.8%, and Medifast reported a revenue decline of 19.4%, topping estimates by 1%. Medifast traded up 5.2% following the results.
Read our full analysis of Estée Lauder’s results here and Medifast’s results here.
There has been positive sentiment among investors in the personal care segment, with share prices up 8.3% on average over the last month. Nature's Sunshine is down 3.3% during the same time and is heading into earnings with an average analyst price target of $25 (compared to the current share price of $11.99).
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.